KRAS and neoplasm: Indeed, SHP2 mediates multiple RTK signals to the RAS pathway, and SHP2 inhibition inhibits RTK-mediated feedback signals in various tumor models in vitro, xenografts, and syngeneic KRAS G12C-mutant pancreatic ductal adenocarcinoma (PDAC) and NSCLC.